Network meta-analysis comparing the efficacy of biologic treatments for achieving complete resolution of nail psoriasis
(2022) In Journal of Dermatological Treatment 33(3). p.1652-1660- Abstract
Background: Nail psoriasis (NP) is common and of high importance in patients with psoriasis. Complete resolution of NP at week 24‒26 is an unambiguous nail outcome accessible for indirect treatment comparison of biologics. Objective: To evaluate the comparative efficacy of approved biologics in achieving complete resolution of NP at week 24‒26. Methods: A network meta-analysis (NMA) was conducted to indirectly compare the efficacy of six biologics in achieving complete resolution of NP at week 24‒26 in patients with moderate-to-severe psoriasis and concomitant NP. Complete resolution of NP was defined as a score of zero on the Nail Psoriasis Severity Index (NAPSI), modified NAPSI (mNAPSI) or Physician’s Global Assessment of Fingernails... (More)
Background: Nail psoriasis (NP) is common and of high importance in patients with psoriasis. Complete resolution of NP at week 24‒26 is an unambiguous nail outcome accessible for indirect treatment comparison of biologics. Objective: To evaluate the comparative efficacy of approved biologics in achieving complete resolution of NP at week 24‒26. Methods: A network meta-analysis (NMA) was conducted to indirectly compare the efficacy of six biologics in achieving complete resolution of NP at week 24‒26 in patients with moderate-to-severe psoriasis and concomitant NP. Complete resolution of NP was defined as a score of zero on the Nail Psoriasis Severity Index (NAPSI), modified NAPSI (mNAPSI) or Physician’s Global Assessment of Fingernails (PGA-F). Results: The probability of achieving complete resolution of NP was highest for ixekizumab (46.5%; 95% credibility interval [CrI] 35.1‒58.0; Surface Under the Cumulative RAnking curve [SUCRA] 97%), followed by brodalumab (37.0%; 17.0‒61.0; 79%), adalimumab (28.3%; 24.4‒32.4; 62%), guselkumab (27.7%; 21.1‒35.1; 58%), ustekinumab (20.8%; 10.2‒35.2; 37%), and infliximab (0.8%; 0.0‒8.9; 17%). Conclusion: In patients with moderate-to-severe psoriasis and concomitant NP, ixekizumab has the greatest likelihood among approved biologics of achieving complete resolution of NP at week 24‒26. Findings should be interpreted carefully because of inherent study limitations.
(Less)
- author
- Reich, Kristian ; Conrad, Curdin ; Kristensen, Lars Erik LU ; Smith, Saxon D. ; Puig, Luis ; Rich, Phoebe ; Sapin, Christophe ; Holzkaemper, Thorsten ; Koppelhus, Uffe and Schuster, Christopher
- organization
- publishing date
- 2022
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- biologics, complete clearance/resolution of nail psoriasis, ixekizumab, Nail psoriasis, Nail Psoriasis Severity Index (NAPSI), network meta-analysis, Physician’s Global Assessment of Fingernails (PGA-F)
- in
- Journal of Dermatological Treatment
- volume
- 33
- issue
- 3
- pages
- 1652 - 1660
- publisher
- Informa Healthcare
- external identifiers
-
- scopus:85101887332
- pmid:33641593
- ISSN
- 0954-6634
- DOI
- 10.1080/09546634.2021.1892024
- language
- English
- LU publication?
- yes
- additional info
- Publisher Copyright: © 2021 Taylor & Francis Group, LLC.
- id
- 1cb1e1d7-4011-4fbb-8fea-f7e2e8aa6d6c
- date added to LUP
- 2022-01-27 11:16:44
- date last changed
- 2024-06-16 00:33:59
@article{1cb1e1d7-4011-4fbb-8fea-f7e2e8aa6d6c,
abstract = {{<p>Background: Nail psoriasis (NP) is common and of high importance in patients with psoriasis. Complete resolution of NP at week 24‒26 is an unambiguous nail outcome accessible for indirect treatment comparison of biologics. Objective: To evaluate the comparative efficacy of approved biologics in achieving complete resolution of NP at week 24‒26. Methods: A network meta-analysis (NMA) was conducted to indirectly compare the efficacy of six biologics in achieving complete resolution of NP at week 24‒26 in patients with moderate-to-severe psoriasis and concomitant NP. Complete resolution of NP was defined as a score of zero on the Nail Psoriasis Severity Index (NAPSI), modified NAPSI (mNAPSI) or Physician’s Global Assessment of Fingernails (PGA-F). Results: The probability of achieving complete resolution of NP was highest for ixekizumab (46.5%; 95% credibility interval [CrI] 35.1‒58.0; Surface Under the Cumulative RAnking curve [SUCRA] 97%), followed by brodalumab (37.0%; 17.0‒61.0; 79%), adalimumab (28.3%; 24.4‒32.4; 62%), guselkumab (27.7%; 21.1‒35.1; 58%), ustekinumab (20.8%; 10.2‒35.2; 37%), and infliximab (0.8%; 0.0‒8.9; 17%). Conclusion: In patients with moderate-to-severe psoriasis and concomitant NP, ixekizumab has the greatest likelihood among approved biologics of achieving complete resolution of NP at week 24‒26. Findings should be interpreted carefully because of inherent study limitations.</p>}},
author = {{Reich, Kristian and Conrad, Curdin and Kristensen, Lars Erik and Smith, Saxon D. and Puig, Luis and Rich, Phoebe and Sapin, Christophe and Holzkaemper, Thorsten and Koppelhus, Uffe and Schuster, Christopher}},
issn = {{0954-6634}},
keywords = {{biologics; complete clearance/resolution of nail psoriasis; ixekizumab; Nail psoriasis; Nail Psoriasis Severity Index (NAPSI); network meta-analysis; Physician’s Global Assessment of Fingernails (PGA-F)}},
language = {{eng}},
number = {{3}},
pages = {{1652--1660}},
publisher = {{Informa Healthcare}},
series = {{Journal of Dermatological Treatment}},
title = {{Network meta-analysis comparing the efficacy of biologic treatments for achieving complete resolution of nail psoriasis}},
url = {{http://dx.doi.org/10.1080/09546634.2021.1892024}},
doi = {{10.1080/09546634.2021.1892024}},
volume = {{33}},
year = {{2022}},
}